Boston Scientific (BSX) shares have come under pressure after the company issued 2026 guidance that fell short of market expectations, with investors focusing on slowing revenue growth in its electrophysiology segment.

At a share price of $45.29, Boston Scientific has seen pressure build, with the 30 day share price return down 20.28% and the year to date share price return down 52.18%. The 1 year total shareholder return is down 55.32%, pointing to fading momentum despite earlier multi year gains.

If recent volatility around Boston Scientific has you reassessing healthcare exposure, this can be a useful time to scan the wider sector and compare other 41 healthcare AI stocks

With Boston Scientific now trading well below its recent highs after cautious 2026 guidance, the key question is whether the current share price reflects temporary concern around electrophysiology or whether the market is accurately pricing in slower growth ahead.

Most Popular Narrative: 54.2% Undervalued

According to the most followed narrative for Boston Scientific, a fair value of $98.90 is being compared to the latest close at $45.29, creating a wide gap that hinges on how investors view future growth and profitability.

The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons:* Earnings Dilution: The acquisition is expected to be dilutive to adjusted earnings per share (EPS) by approximately $0.06 to $0.08 in the first full year. Investors often react to this "EPS drag" by pulling back, which we've seen in the recent price dips.

Want to see what could justify nearly doubling Boston Scientific's current share price? The narrative leans on faster revenue expansion, richer margins and a premium future earnings multiple. Curious which assumptions really carry that valuation and how the Penumbra deal fits into the model? The full story joins those pieces together.

Result: Fair Value of $98.90 (UNDERVALUED)

However, Boston Scientific still faces key risks, including integration missteps with Penumbra and any disappointment compared with its revenue or margin expectations in core cardiovascular and MedSurg segments.

Next Steps

With sentiment split between caution and opportunity around Boston Scientific, this is a moment to review the evidence yourself and move decisively. To see which potential bright spots others are focused on, check the 4 key rewards.

Looking for more Boston Scientific sized opportunities?

Before moving on, take a moment to hunt for fresh ideas beyond Boston Scientific, or you may miss stocks that better match your risk and return preferences.

• Target potential mispricing by scanning companies that combine quality with value through the 45 high quality undervalued stocks.
• Prioritize resilience by checking out businesses that score well on stability with the 66 resilient stocks with low risk scores.
• Seek future standouts early by reviewing companies with strong fundamentals in the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.